Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a … Read more
Market Cap & Net Worth: Polaryx Therapeutics, Inc. Common Stock (PLYX)
Polaryx Therapeutics, Inc. Common Stock (NASDAQ:PLYX) has a market capitalization of $52.74K ($52.74K) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #42149 globally and #13662 in its home market, demonstrating a 59.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Polaryx Therapeutics, Inc. Common Stock's stock price $5.63 by its total outstanding shares 9368 (9.37K).
Polaryx Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Polaryx Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $52.74K to $52.74K (0.00% CAGR).
Polaryx Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Polaryx Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PLYX by Market Capitalization
Companies near Polaryx Therapeutics, Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to Polaryx Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Polaryx Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Polaryx Therapeutics, Inc. Common Stock's market cap moved from $52.74K to $ 52.74K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.74K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Polaryx Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.74K USD |
| MoneyControl | $52.74K USD |
| MarketWatch | $52.74K USD |
| marketcap.company | $52.74K USD |
| Reuters | $52.74K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.